期刊文献+

中国人类疾病临床资源样本库建设调研初探 被引量:4

Human disease biobanking in China: results from a primary survey and perspectives
下载PDF
导出
摘要 目的通过收集中国人类疾病临床资源样本库的基本信息和相关资料,初步了解中国疾病临床资源样本库的组织架构、规模及其综合能力。方法采用问卷与访谈方式,对11家样本库的设立初衷、组织架构、样本库利用和可持续发展等进行调研,在中国首次利用循证研究模式来论证人类疾病样本库的顶层设计、管理规范和国际合作导向。结果调研中绝大多数样本库附属于医院或科研院所,依靠国家、地方课题和医院专项基金建立;三分之二的样本库成立于最近5年,建立的初衷是满足特定疾病或基础研究的需要;样本库工作人员的构成不尽合理;样本库储存样本的数量不同、类型和方式多样;样本库具有较强的分子生物学检测能力,但病理和细胞学检测能力则相对较弱;样本的有效利用和样本库长期运营经费是未来需要重点关注的问题。结论中国疾病临床资源样本库建设正处于快速上升期,当务之急是加强样本库的顶层设计和管理规范、建立符合国际规范的质控标准、提高专业人员的管理和技术水平、建立符合中国国情的伦理规范。 Objective To establish knowledge of the top-level framework design and interna-tional cooperation , the organization and functioning of biobanks in China by collecting the basic infor -mation and related data .Methods A questionnaire survey was applied on 11 typical disease-oriented biobanks , collecting information on the organizational structure , form of staff, specimen collection and effective usages , and sustainable development of biobanks. Results Almost all biobanks were affiliated within hospital and/or academic institution .The national and provincial government grants , the hospital special funds were the most common and largest sources of establishment funding of these biobanks .Two-third biobanks were established within the last five years .Nearly all biobanks were established intentionally to address particular or general research .The personnel structure of most biobanks was unreasonable .There were tremendous diversity in the biobank sizes and types of speci-men collections .Most biobanks had enough capability in molecular and genetic analysis , whereas their pathological and cellular detection capability was relatively weak .The underutilization of speci-mens and long-term funding of biobanks were the most important issues which should be concerned in future .Conclusion The establishment and development of human diseases biobanks in China are in rapid growth stage .The most imperative issues are to establish the top-level framework structure , strengthen the management and ethical principles , construct the international standard specimens collection and quality control level and develop the professional training .
出处 《转化医学杂志》 2015年第6期324-328,341,共6页 Translational Medicine Journal
基金 北京市科学技术委员会课题(D131100005313016)
关键词 生物样本库 转化医学 调查研究 Biobanks Translational medicine Survey
  • 相关文献

参考文献15

二级参考文献89

  • 1陈仕林,程子敏.检验质量中不容忽视的分析前因素[J].检验医学与临床,2005,2(1):32-33. 被引量:7
  • 2季加孚.北京大学临床肿瘤学院标本库的建设[J].北京大学学报(医学版),2005,37(3):329-330. 被引量:81
  • 3孙磊.美国组织库事业发展情况[J].中国修复重建外科杂志,2006,20(11):1145-1146. 被引量:13
  • 4方福德.与肿瘤个体化诊疗相关的科技计划[J].中华肿瘤杂志,2006,28(10):798-798. 被引量:6
  • 5Lu Yaohuai. On the Issues of Body--Rights in Contemporary China--A Case Analysis[J]. Contemporary Chinese Thought, 2007,(39)2:33--43.
  • 6Doering O. Culture Challenges in Bioethics Understanding:Towards a Joint Science Agenda between China and Germany[M]//Li Wenchao, Hans Poser. The Ethics of Today' s Science and Technology. A German--Chinese Approach, Munster: LIT, 2008 : 212-- 223.
  • 7Gunther T. Juridification of Social Spheres. A Comparative Analysis in the Arenas of Labor, Corporate Antitrust and Social Welfare Law[M]. Berlin/New York: Walter de Gruyter, 1987.
  • 8Doering O. "Social Darwinism, Liberal Eugenics, and the Example of Bioethics in China", in Re--ethnicizing the Minds? [M]// Botz --Bornstein T, Hengelbrock J. Cultural Revival in Contemporary Thought. Amsterdam/New York:Rodopi,2006: 137--148.
  • 9HUGO. Ethics Committee: Statement on Benefit--Sharing[EB/ OL]. (2000--04 -- 09) [2009 -- 09 -- 15]. http://www, hugo-- international, org/hugo/benefit, html.
  • 10Doering O. Biomedical Research and Ethical Regulations in China: Some Observations about Gene Therapy, Human Research, and Struggles of Interest[M]// Niewohner J, Amsterdam C T. Gene Therapy: Prospective Technology Assessment in its Societal Context. Berlin.. Max--Delbrueck Centre, 2006 : 143-- 158.

共引文献152

同被引文献36

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部